Entrada Therapeutics (TRDA) Return on Sales (2023 - 2025)
Historic Return on Sales for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to 27.37%.
- Entrada Therapeutics' Return on Sales fell 266600.0% to 27.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.68%, marking a year-over-year decrease of 19400.0%. This contributed to the annual value of 0.31% for FY2024, which is 3600.0% up from last year.
- Latest data reveals that Entrada Therapeutics reported Return on Sales of 27.37% as of Q3 2025, which was down 266600.0% from 22.12% recorded in Q2 2025.
- Entrada Therapeutics' 5-year Return on Sales high stood at 0.81% for Q3 2023, and its period low was 27.37% during Q3 2025.
- In the last 3 years, Entrada Therapeutics' Return on Sales had a median value of 0.27% in 2023 and averaged 4.65%.
- Per our database at Business Quant, Entrada Therapeutics' Return on Sales soared by 20100bps in 2024 and then plummeted by -266600bps in 2025.
- Entrada Therapeutics' Return on Sales (Quarter) stood at 0.23% in 2023, then skyrocketed by 113bps to 0.03% in 2024, then tumbled by -92742bps to 27.37% in 2025.
- Its Return on Sales was 27.37% in Q3 2025, compared to 22.12% in Q2 2025 and 0.84% in Q1 2025.